MedTrace Logo

Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome

NCT02535611 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2020-10-06

Study results available
· View outcomes & findings →

Summary

The researchers aim to investigate the effect of memantine on stroke outcome in a randomized double-blind placebo-controlled clinical trial.

Conditions

Interventions

DRUG

Placebo

Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.

DRUG

Memantine

Beside the usual treatment for ischemic stroke this group will be treated by memantine.

Sponsors & Collaborators

  • Mazandaran University of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-10-31
Completion
2017-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02535611 on ClinicalTrials.gov